Panbela Therapeutics (NASDAQ:PBLA) Trading Down 2.7%

Shares of Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell 2.7% during mid-day trading on Friday . The company traded as low as $0.33 and last traded at $0.36. 2,808 shares traded hands during trading, a decline of 99% from the average session volume of 281,870 shares. The stock had previously closed at $0.37.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of Panbela Therapeutics in a report on Thursday, August 15th.

Panbela Therapeutics Stock Down 2.7 %

The business has a 50-day moving average of $0.36 and a two-hundred day moving average of $0.50. The firm has a market capitalization of $1.25 million, a price-to-earnings ratio of 0.00 and a beta of 1.62.

Panbela Therapeutics (NASDAQ:PBLA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.47) earnings per share for the quarter, topping the consensus estimate of ($2.07) by $0.60. Equities analysts predict that Panbela Therapeutics, Inc. will post -6.76 EPS for the current fiscal year.

About Panbela Therapeutics

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.